All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-06-04T15:43:53.000Z

3 things you should consider when treating frail patients

Bookmark this article

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Sonja Zweegman, Amsterdam UMC, Amsterdam, NL. We asked, Which 3 things should you consider when treating frail patients? 

3 things you should consider when treating frail patients

In this video, Zweegman outlines the levels of frailty in patients over 70, and how therapies such as dexamethasone and lenalidomide can be adapted for intermediate–fit and frail patients. She highlights a recent trial that found patients defined as frail based on their age had superior progression-free survival than those defined as frail because of comorbidities.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox